Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia
Condition(s):Leukemia, Lymphoblastic, ChronicLast Updated:September 8, 2021Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Leukemia, Lymphoblastic, ChronicLast Updated:September 8, 2021Active, not recruiting
Condition(s):Hodgkin DiseaseLast Updated:February 24, 2016Completed
Condition(s):Relapsing Multiple SclerosisLast Updated:December 6, 2023Recruiting
Condition(s):Waldenstrom MacroglobulinaemiaLast Updated:May 30, 2017Completed
Condition(s):Relapsing Multiple SclerosisLast Updated:January 18, 2024Recruiting
Condition(s):Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell LymphomaLast Updated:July 30, 2014Terminated
Condition(s):Lymphoma, Non-HodgkinsLast Updated:August 26, 2015Terminated
Condition(s):Chronic Lymphocytic Leukemia (CLL)Last Updated:July 20, 2011Withdrawn
Condition(s):Chronic Lymphocytic Leukemia; Small Lymphocytic LymphomaLast Updated:December 15, 2015Terminated
Condition(s):CLLLast Updated:May 8, 2018Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.